X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.
Lead Product(s): Aumolertinib
Therapeutic Area: Oncology Product Name: EQ143
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
Lead Product(s): Aumolertinib
Therapeutic Area: Oncology Product Name: EQ143
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abdul Latif Jameel Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 22, 2021
Details:
Proceeds expand balance sheet to ~$2.0 billion and will be used for “new pharma” platforms. EQRx’s growing pipeline includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and other clinical-stage programs.
Lead Product(s): Aumolertinib
Therapeutic Area: Oncology Product Name: EQ143
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CM Life Sciences
Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million
Deal Type: Merger August 06, 2021
Details:
Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).
Lead Product(s): Aumolertinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: EQRx
Deal Size: Undisclosed Upfront Cash: $100.0 million
Deal Type: Licensing Agreement July 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
